Aldosterone

CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

Retrieved on: 
Wednesday, June 1, 2022
Kidney, Glomerular filtration rate, Primary aldosteronism, Adult, Achievement, Time, Stroke, Research, Degenerative disease, Safety, Annual report, American College, Security (finance), Inflammation, U.S. Securities and Exchange Commission, Diabetes, Blood, Hypertension, Biomarker, Chronic kidney disease, GFR, American College of Cardiology, GLOBE, Patient, Risk, RAAS, SBP, COVID-19, Death, Glomerulonephritis, Kidney disease, SEC, Population, American Heart Association, Cardiology, Blood pressure, CKD, Aldosterone, Disclosure, Pharmaceutical industry, Collection

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease (CKD).

Key Points: 
  • WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease (CKD).
  • Over 37 million people in the United States suffer from chronic kidney disease and progressive loss of kidney function.
  • Baxdrostat is a highly selective aldosterone synthase inhibitor that can significantly reduce aldosterone levels, offering the potential to not only improve uncontrolled blood pressure in CKD patients, but also ameliorate the negative impacts of aldosterone on kidney function.
  • The figHTN-CKD trial is a randomized, double-blind, placebo-controlled, multicenter, parallel-group, Phase 2 clinical trial designed to assess the safety and efficacy of baxdrostat (CIN-107) in patients with uncontrolled hypertension and CKD.

CinCor Pharma to Present at the Jefferies Healthcare Conference

Retrieved on: 
Tuesday, May 31, 2022
Risk, Population, Jefferies, Primary aldosteronism, American College, Hypertension, Degenerative disease, Cardiology, Patient, NASDAQ, American Heart Association, CINC, Stroke, Adult, Kidney disease, Conference, American College of Cardiology, Aldosterone, Death, GLOBE, Pharmaceutical industry, Collection

WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York.

Key Points: 
  • WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York.
  • The CinCor management team will give a corporate presentation on June 9, 2022, at 9 AM EDT.
  • The CinCor management team will also participate in one-on-one investor meetings during the event.
  • Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.

Global Chronic Kidney Disease (CKD) Pipeline Landscape Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Other Health, Gynecomastia, Chronic kidney disease, Risk, Gout, CKD, Waste, Metabolic disorder, Blood, II, Hypertension, Blood pressure, News, Patient, Hirsutism, Moderate, Mergers and acquisitions, Obesity, Probiotic, MRA, Clinical trial, Arthritis, Progesterone, Nutrient, III, Technology, LAP, Empagliflozin, Aldosterone, NDA, TGF, Boehringer Ingelheim, Therapy, Kidney, SGLT, Discovery, Acquisition, KBP, Pharmaceutical industry, Poultry, Hyperuricemia

This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.

Key Points: 
  • This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.
  • A detailed picture of the Chronic-kidney-disease-chronic-renal-failure pipeline landscape is provided which includes the disease overview and Chronic-kidney-disease-chronic-renal-failure treatment guidelines.
  • The assessment part of the report embraces, in depth Chronic-kidney-disease-chronic-renal-failure commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic-kidney-disease-chronic-renal-failure R&D.

CinCor Pharma to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 17, 2022
UBS, Risk, Population, Primary aldosteronism, American College, Hypertension, Degenerative disease, Cardiology, Patient, NASDAQ, American Heart Association, CINC, Stroke, Adult, Kidney disease, Conference, American College of Cardiology, Aldosterone, Death, GLOBE, Video game, Pharmaceutical industry, Collection

The live presentation at the UBS Global Healthcare Conference will be on Tuesday, May 24, 2022, at 7:45 AM EST in New York, New York.

Key Points: 
  • The live presentation at the UBS Global Healthcare Conference will be on Tuesday, May 24, 2022, at 7:45 AM EST in New York, New York.
  • The CinCor management team will participate in one-on-one investor meetings during both events.
  • Investors interested in meeting with CinCor at the conference should contact their respective H.C. Wainwright or UBS representatives.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.

CinCor Reports First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, American College of Cardiology, U.S. Securities and Exchange Commission, Population, American College, Hypertension, CKD, NASDAQ, Aldosterone, GLOBE, Kidney disease, Chronic kidney disease, Chemistry, Degenerative disease, Stroke, Disclosure, Time, Death, Patient, Security (finance), Risk, Administration, Annual report, Research and development, Cardiology, Adult, R, American Heart Association, Achievement, SEC, G&A, Primary aldosteronism, Research, Phase II, IPO, CINC, Pharmaceutical industry, Collection

WALTHAM, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • WALTHAM, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • In March 2022, the BrigHtn Phase 2 trial of baxdrostat (CIN-107) for treatment-resistant hypertension (rHTN) completed enrollment with 275 patients randomized.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit

Retrieved on: 
Tuesday, April 19, 2022
Primary aldosteronism, Death, Hypertension, Population, Adult, Degenerative disease, Stroke, Risk, GLOBE, Bay, Cardiology, Patient, Jefferies, Kidney disease, American College of Cardiology, American College, American Heart Association, Aldosterone, Pharmaceutical industry, Collection

WALTHAM,Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida.

Key Points: 
  • WALTHAM,Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida.
  • The CinCor management team will participate in one-on-one investor meetings during the event.
  • Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.

DGAP-News: Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

Retrieved on: 
Tuesday, April 12, 2022
PAN, Nuclear medicine, Primary aldosteronism, TecDAX, Diagnosis, Radiopharmaceutical, III, APA, European Medicines Agency, Lymphoma, RUMC, Multiple myeloma, Aldosterone, Deutsch, Hypertension, Berlin, Prevalence, ISIN, Inflammation, Radboud University Medical Center, Review, Adrenal insufficiency, CXCR4, EMA, PET, BAH, Patient, Phase, AVS, Pharmaceutical industry, Medical imaging, Conn

Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.

Key Points: 
  • Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.
  • Developed by PentixaPharm, PENTIXAFOR is an innovative imaging PET tracer that targets the chemokine-4 receptor (CXCR4) and is used to diagnose various oncological and inflammatory diseases.
  • The CASTUS study is a clinical research programme aiming to evaluate the accuracy of PENTIXAFOR in the diagnosis of primary aldosteronism.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX), the owner of the rights to the underlying [68Ga]Ga-PentixaFor PET compound, is supporting the RUMC team by providing PENTIXAFOR.

CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 22, 2022
Risk, Therapy, Blood pressure, Hypertension, Adult, American College of Cardiology, SEC, Research, Aldosterone, CEO, American College, Time, Cardiology, GLOBE, Series, Research and development, Security (finance), Death, Population, CMC, CINC, Achievement, Â, G&A, Director, U.S. Securities and Exchange Commission, Drug, IPO, Chronic kidney disease, General Atlantic, Karuna, NASDAQ, Russell, ID, Board, Annual report, American Heart Association, Disclosure, Patient, Administration, Company, Form 10-K, Leadership, Phase II, Kidney disease, Stroke, COVID-19, Degenerative disease, Amarin Corporation, R, Primary aldosteronism, Pharmaceutical industry, Management, Collection

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.
  • In December 2021, the first patient was dosed in the Phase 2 HALO trial which is evaluating CIN-107 in patients with uncontrolled hypertension.
  • , was named as Chief Medical Officer, after having been appointed as Executive Vice President, Clinical Development in August 2021.
  • CinCor management will hold a conference call and webcast today at 8:30 AM Eastern Time to review the companys financial and operating results and to provide a corporate update.

CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes

Retrieved on: 
Thursday, March 17, 2022
Death, Index, Risk, GLOBE, American Heart Association, Patient, Russell Indexes, American College of Cardiology, Organization, COVID-19, Aldosterone, Primary aldosteronism, FTSE Russell, Hypertension, IPO, American College, Security (finance), NASDAQ, Adult, CINC, Stroke, Degenerative disease, Kidney disease, Company, Research, Population, Cardiology, Collection, U.S. Securities and Exchange Commission, Russell, Pharmaceutical industry

The inclusion of CinCor Pharma in the Russell 2000 and Russell 3000 Indexes builds on the momentum we have experienced following the close of our successful IPO in January, said Marc de Garidel, Chief Executive Officer of CinCor.

Key Points: 
  • The inclusion of CinCor Pharma in the Russell 2000 and Russell 3000 Indexes builds on the momentum we have experienced following the close of our successful IPO in January, said Marc de Garidel, Chief Executive Officer of CinCor.
  • The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market.
  • The index is a subset of the Russell 3000 Index and represents approximately 10 percent of the total market capitalization of that index.
  • Russell indexes are part of FTSE Russell, a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide.

Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Tuesday, March 15, 2022
Therapy, Wedbush Securities, Jefferies Group, Blood pressure, Chronic kidney disease, Patient, Merrill Lynch, Pierce, Fenner & Smith, Inc. v. Dabit, Plasma, Nasdaq, Hormone, CFO, Aldosterone, Hypertension, CBO, Company, Mitsubishi Tanabe Pharma, CYP11B2, Merrill (company), Industry, Vifor Pharma, Pharmaceutical industry

PHILADELPHIA, March 15, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension, today announced the appointment of Adam Levy as the company's new Chief Financial Officer (CFO) and Chief Business Officer (CBO).

Key Points: 
  • PHILADELPHIA, March 15, 2022 /PRNewswire/ -- Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension, today announced the appointment of Adam Levy as the company's new Chief Financial Officer (CFO) and Chief Business Officer (CBO).
  • "We are pleased to announce Adam's appointment and welcome him to the Mineralys leadership team.
  • Adam brings more than two decades of operational and transactional expertise in biotech and investment banking.
  • As CBO at miRagen Therapeutics, Inc., Adam had broad operational responsibilities and led several business development transactions and capital raises, including a listing on the Nasdaq.